Balancing Act: Navigating Treatments for Psoriasis and Prevention of Psoriatic Arthritis

This activity is part of a series


Melodie S. Young, MSN, APRN, A/GNP-BC
Dermatology NP
Mindful Dermatology and Modern Research Associates
Melodie S. Young, MSN, APRN, A/GNP-BC

Melodie Young has more than 30 years in dermatology as a nurse practitioner and has focused her career on immune-mediated skin disease. She has been the Principal Investigator or Sub-Investigator in more than 80 clinical trials and has more than 40 scholarly publications.  She is the former Director of the Baylor Psoriasis Center, National Psoriasis Tissue Bank, and a former member of the Medical Advisory Board of the National Psoriasis Foundation. Young is a founding member of the International Psoriasis Council.

Statement of Need

The treatment landscape for psoriasis (PsO) and psoriatic arthritis (PsA) is evolving, yet many novel approaches have limitations. Several Janus kinase inhibitors (JAKis) have indications for only one of the two conditions; others carry black box warnings from the U.S. Food and Drug Administration (FDA) of which patients remain wary. Biologics are a safe and efficacious treatment option despite diversity in mechanisms of action (MOAs), though only some have indications for both PsO and PsA. Biosimilars present another approved option for PsO/PsA treatment, yet clinicians lack understanding of their role and development. PsA prevention in patients with PsO is another area of consideration for clinicians, particularly for nurse practitioners (NPs) and physician associates (PAs) involved in treatment decision-making. Clinicians collaborating with a multidisciplinary care team require dedicated education on all applicable treatment options to provide the best possible standard of care for patients with PsO and/or PsA.

In the third activity of this CME Outfitters BriefCase series, expert faculty utilize case-based learning to instruct learners on incorporating efficacy and safety data for biologics indicated for PsO and PsA in patients as part of treatment decision-making.

Learning Objectives

At the conclusion of this activity, learners will be able to better:

  • Incorporate efficacy and safety data for biologics indicated for PsO and PsA in patients as part of treatment decision-making

Financial Support

This activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.- both are Johnson & Johnson companies.

Target Audience

Physicians, nurse practitioners (NPs), and physician associates (PAs) specializing in dermatology and rheumatology

Credit Information

Jointly Accredited Provider

In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional (IPCE) 0.5

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education Credit for learning and change.

Physicians (ACCME) 0.5

CME Outfitters, LLC, designates this Enduring Material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 0.5

This activity is designated for 0.50 contact hours.

California Residents: This continuing nursing education activity was approved by the California Board of Registered Nursing. CME Outfitters LLC’s provider number is CEP15510.

Note to Nurse Practitioners: the content of this CNE activity pertains to Pharmacology.

PAs (AAPA) 0.5

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until 03/07/25. PAs should only claim credit commensurate with the extent of their participation.


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Disclosure Declaration

Ms. Young reports no financial relationships to disclose.

The following individuals have no financial relationships to disclose: 

Jeffrey Hefland, DO (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Keshia Pitt, PhD (Planning Committee)
John Jones, PharmD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

Obtaining Credit

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).


Balancing Act: Navigating Treatments for Psoriasis and Prevention of Psoriatic Arthritis
Event Date: 03/07/2024